Neurofibromatosis and Lymphoma oncogenesis - NFL
The team’s scientific project focuses on characterising the molecular and cellular mechanisms governing the development of lymphomas, in particular T lymphomas derived from follicular helper T cells (led by angio-immunoblastic T lymphoma) and cutaneous T lymphomas, and Schwann cell-derived tumours in neurofibromatosis 1 (NF1), two cancer models characterised by the accumulation of sequential genetic alterations that are still incompletely known and for which no effective treatment is currently available.
The team is rich in internationally recognized principal investigators in the fields of T-cell lymphoma oncogenesis (Pr Philippe Gaulard, Dr François Lemonnier), including cutaneous lymphomas (Pr Nicolas Ortonne), the study of early events in hematopoietic progenitors (Pr Wagner Ballon and Dr Ivan Sloma), translational research on T and B lymphomas (Pr Marie-Hélène Delfau, Pr Corinne Haioun), and neurosciences and Neurofibromatosis 1 (Pr Pierre Wolkenstein and Pr Benoît Funalot), with particular expertise in NF1 mouse models (Pr Piotr Topilko).
The team is interested in the nature and functional consequences of the molecular alterations characterising tumour cells, paying particular attention to the hierarchy of genetic events, the nature of the cells involved in the initiating events, their phenotypic aberrations and the interactions of tumour cells with their environment. The molecular analyses we are currently conducting benefit from innovative technologies, such as single cell sequencing, which we have recently applied to the study of both cancer models. We are also developing in vitro and ex vivo proofs of concept for new therapeutic approaches, taking advantage of the study of lines, primary cells and mouse models. Recently, our studies in the field of T-cell lymphoma have led to the initiation of a therapeutic trial (ORACLE – ClinicalTrials.gov Identifier: NCT03593018).
The ultimate aim of these projects is to identify new therapeutic targets based on chemical inhibitors or monoclonal antibodies, which will make it possible to improve patient care.
The work is based in particular on :
– Cohorts of annotated patients from the Neurofibromatosis reference centre directed by Pr Pierre Wolkenstein or included in the LYSA trials (Lymphoma Study Association; C Haioun and MH Delfau members of the board);
– The collections of tumour samples available on the Henri Mondor site, conserved in the biological resource platform, in connection with national expertise networks (and Lymphopath network labelled by the INCa, directed by Pr Philippe Gaulard), established from national research projects (PHRC TENOMIC (PI P. Gaulard) and KIRs (PI N Ortonne),…), or prospective (collection of cutaneous lymphomas, LYCUT) ;
– Interactions with national and international academic partners and research funding agencies, including an international project funded by the Leukemia Lymphoma Study Association (LLS) for T-cell lymphomas and the Neurofibromatosis Therapeutic Acceleration Program NTAP consortium for NF1, in close collaboration with Johns Hopkins University in Baltimore (Maryland, USA);
– Industrial partnerships/collaborations (partly through the Carnot CALYM Institute for Lymphomas) which have led to the establishment of collaboration contracts with pharmaceutical laboratories;
– The establishment of mouse models developed by the team (genetically modified NF1 mice and PDX-type xenograft mice). In particular, several members of our team, under the responsibility of Pr Piotr Topilko, are basing a large part of their research on the recently established NF1 mouse model which has already made it possible to identify the cells of origin of human neurofibromas during NF1. This offers the unique advantage of summarising most aspects of human disease, particularly with regard to Schwann cell-derived tumours.
Areas of research :
– Characterisation of the cells of origin, molecular alterations and oncogenic mechanisms involved in T lymphomas and Schwannian tumours of Neurofibromatosis 1.
– New therapeutic targets targeting tumour cells and the environment of T lymphomas and NF1 tumours
Key words :
oncogenesis, T lymphomas, neurofibromatosis 1
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, Amara N, Adélaïde J, Guille A, Schiano JM, Tesson B, Traverse‐Glehen A, Chenard MP, Mescam L, Moreau A, Chassagne‐Clement C, Somja J, Escudié F, André M, Martin N, Lacroix L, Lemonnier F, Hamy‐Petit AS, Reyal F, Bannier M, Oberic L, Prade N, Frénois FX, Beldi‐Ferchiou A, Delfau‐Larue MH, Bouabdallah R, Birnbaum D, Brousset P, Xerri L, Gaulard P. Gene alterations in epigenetic modifiers and JAK‐STAT signaling are frequent in breast implant‐associated ALCL.Blood. 2020 Jan 30;135(5):360-370.
Drieux F, Ruminy P, Abdel‐Sater A, Lemonnier F, Viailly PJ, Fataccioli V, Machand V, Bisig B, Letourneau A, Parrens M, Bossard C, Bruneau J, Dobay P, Veresezan L, Dupuy A, Pujals A, Robe C, Sako N, Copie‐Bergman C, Delfau‐Larue MH, Picquenot JM, Tilly H, Delarue R, Jardin F, de Leval L, Gaulard P; TENOMIC. Defining the signatures of peripheral T‐cell lymphoma, with a targeted 20‐markers gene expression profiling assay (RT‐MLPA).Haematologica. 2019 Sep 5. pii: haematol.2019.226647. doi: 10.3324/haematol.2019.226647. [Epub ahead of print]
Radomska KJ, Coulpier F, Gresset A, Schmitt A, Debbiche A, Lemoine S, Wolkenstein P, Vallat JM, Charnay P, Topilko P. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells.Cancer Discovery. 2019;9(1):130-147.
Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A. Cutaneous neurofibromas: Current clinical and pathologic issues.Neurology. 2018;91(2 Supplement 1):S5-S13
Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, Pelletier L, Marcais A, Robe C, Fataccioli V, Haioun C, Hermine O, Gaulard P, Delarue R. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.Blood 2018;22;132(21):2305-2309.
Vallois D*, Dupuy A*, Lemonnier F, Allen G, Missiaglia E, Fataccioli V, Ortonne N, Clavert A, Delarue R, Rousselet M-C, Fabiani B, Llamas-Gutierrez F, Ogawa S, Thome M, Ko YH, Kataoka K, Gaulard P*, de Leval L*. RNA fusions involving CD28 are rare in peripheral T-Cell lymphomas and concentrate mainly in those derived from follicular helper T cells.Haematologica 2018;103(8):e360.
Leclaire Alirkilicarslan A, Dupuy A, Pujals A, Parrens M, Vergier B, Robson A, Delfau-Larue M-H, Ingen-Housz-Oro S, Chosidow O, Haioun C, Beylot-Barry M, Merlio J-P, Copie-Bergman C, Gaulard P, Ortonne N. Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.Am. J. Surg. Pathol. 2017;41:1581–92.
Lemonnier F, Cairns RA, Inoue S, Li WY, Dupuy A, Broutin S, Martin N, Fataccioli V, Pelletier R, Wakeham A, Snow BE, de Leval L, Pujals A, Haioun C, Paci A, Tobin ER, Narayanaswamy R, Yen K, Jin S, Gaulard P, Mak TW. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.Proc Natl Acad Sci U S A 2016;113:15084–9.
Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais J-P, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P*, de Leval L*. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.Blood 2016;128:1490–1502.
- Responsable : Philippe Gaulard
- Responsable délégué (e) : Nicolas Ortonne
- Enseignant-Chercheur : Marie-Hélène Delfau-Larue, Loëtitia Favre, Benoit Funalot, Philippe Gaulard, Jérôme Giustiniani, Corinne Haioun, François Lemonnier, Nicolas Ortonne, Anaïs Pujals, Ivan Sloma, Sihem Tarfi, Piotr Topilko, Orianne Wagner-Ballon, Pierre Wolkenstein
- Post doctorant : Katarzyna Radomska, Nouhoum Sako, Antoine Zalc
- Doctorant : Amandine Decroos, Fanny Drieux, Aurélie Dupuy, Myriam Mansour, Diane-Laure Mboumba, Pernelle Pulh, Serge Skrek, Gamze Tari, Violaine Tran-Quang
- Ingénieur : Fanny Coulpier, Virginie Fataccioli, Laure Lecerf-Ben Ali, Laura Pelletier
- Technicien : Maryse Baïa, Cyrielle Robe
- Gestionnaire : Claudia Grangetaud
- Stagiaire : Axel André, Aurélien Beaude, Elisa Boudali, Anais Brunet, Marine Cohen, Pierre Reimbold
IMRB – Inserm U955
Neurofibromatosis and Lymphoma oncogenesis (Team Ortonne)
Building R – 1st floor
Hôpital Henri Mondor
51, avenue du Maréchal De Lattre de Tassigny
Administrative assistant – Contact
Tél. : +33-1 49 81 37 76
Hepatocellular carcinoma is responsible for one third of cancer deaths worldwide, and most often develops in a context of chronic inflammation. While the immune microenvironment of tumours plays a decisive role in their evolution and is the subject of numerous studies, the role of immunity during the early stages of carcinogenesis remains little studied. In […]Read more
The family Bunyaviridae is a large but unfamiliar group of viruses with more than 300 members with a spherical and helical envelope. Viruses of this family can infect a wide range of hosts, from mosquitoes to marsupials and from thrips to tomatoes. Several of the Bunyaviridae cause serious disease in humans; they represent a growing […]Read more
VRI (Vaccine Research Institute)/ INSERM/UPEC (U955, IMRB) in collaboration with several Inserm and IRD teams has just published a study in Nature Communications on 24 July showing that Ebola survivors suffer serious immune system sequelae two years after their disease. Continuing to wreak havoc in the Democratic Republic of Congo four years after the […]Read more